FOLFIRI-HD

FOLFIRI-HD (High-Dose FOLFIRI) is a chemotherapy combination used primarily for treating metastatic colorectal cancer. It consists of the same drugs as standard FOLFIRI but with a higher dose of irinotecan (260 mg/m² compared to the standard 180 mg/m²). This regimen is specifically designed for patients with certain UGT1A1 genotypes (typically *UGT1A1*6/6 or *UGT1A1*6/7) who can tolerate higher doses of irinotecan without experiencing severe toxicity. Clinical trials have shown that FOLFIRI-HD achieves higher objective response rates (67.5% vs 43.6% with standard FOLFIRI) in patients with appropriate genotypes, without significantly increasing severe toxicity. **Administration:** - Irinotecan: 260 mg/m² (often 220 mg/m² during the first cycle) by two-hour infusion - Leucovorin: 100 mg/m² - 5-FU: 400 mg/m² bolus over 10 minutes followed by continuous infusion of 5-FU at 2400 mg/m² over 46 hours Cycles are repeated every two weeks. **Efficacy and Safety:** Higher objective response rates compared to standard FOLFIRI, acceptable safety profile in selected patients, potential to increase complete clearance of liver metastases when combined with surgery/ablation. Common grade 3-4 toxicities include neutropenia, diarrhea, and asthenia.

Other names

High-dose FOLFIRIHD-FOLFIRI